Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Beginning Cash Balance (2016 - 2025)

Historic Beginning Cash Balance for Northwest Biotherapeutics (NWBO) over the last 9 years, with Q4 2020 value amounting to $315000.0.

  • Northwest Biotherapeutics' Beginning Cash Balance changed N/A to $315000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $379000.0, marking a year-over-year increase of 1519.76%. This contributed to the annual value of $379000.0 for FY2020, which is 1519.76% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Beginning Cash Balance stood at $315000.0 for Q4 2020.
  • Over the past 5 years, Northwest Biotherapeutics' Beginning Cash Balance peaked at $764000.0 during Q3 2017, and registered a low of $41000.0 during Q4 2018.
  • Moreover, its 4-year median value for Beginning Cash Balance was $322000.0 (2019), whereas its average is $352500.0.
  • Data for Northwest Biotherapeutics' Beginning Cash Balance shows a peak YoY increase of 25466.67% (in 2018) and a maximum YoY decrease of 8828.57% (in 2018) over the last 5 years.
  • Northwest Biotherapeutics' Beginning Cash Balance (Quarter) stood at $350000.0 in 2017, then crashed by 88.29% to $41000.0 in 2018, then surged by 702.44% to $329000.0 in 2019, then decreased by 4.26% to $315000.0 in 2020.
  • Its Beginning Cash Balance was $315000.0 in Q4 2020, compared to $64000.0 in Q1 2020 and $329000.0 in Q1 2019.